NCT06620692View on ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients with Psoriasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Psoriasis
Interventions
DRUG

5% GM-XANTHO [GM-XAN003]

5% GM-XANTHO \[GM-XAN003\]

DRUG

Placebo

The placebo

All Listed Sponsors
collaborator

Virginia Contract Research Organization Co., Ltd.

OTHER

lead

Xantho Biotechnology Co., LTD

INDUSTRY